Survival of Medicare fee-for-service chemotherapy patients by site of care
Few studies compare cancer survival outcomes across multiple cancer treatment facility types simultaneously. This report compares the 36-month cancer survival rate by treatment facility type for 46,762 Medicare fee-for-service patients treated with chemotherapy under the Medicare Part B benefit for breast, colon, lung, ovarian, pancreatic, or prostate cancer. It compares prospective payment system-exempt cancer hospitals to National Cancer Institute-designated cancer centers, teaching hospitals, and all other hospitals.
This report was commissioned by the Alliance of Dedicated Cancer Centers.
About the Author(s)
Survival of Medicare fee-for-service chemotherapy patients by site of care
This report compares the 36-month cancer survival rate by treatment facility type for 46,762 Medicare fee-for-service patients treated with chemotherapy under the Medicare Part B benefit for breast, colon, lung, ovarian, pancreatic, or prostate cancer.